Serum Biomarkers of Renal Fibrosis: A Systematic Review
Chronic kidney disease (CKD) is a widely diffuse pathological condition which deeply impacts upon an affected patient’s quality of life and its worldwide rate is predicted to further rise. The main biological mechanism underlying CKD is renal fibrosis, a non-reversible process representing, for the...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/22/14139 |
| _version_ | 1797465132482166784 |
|---|---|
| author | Alice Barinotti Massimo Radin Irene Cecchi Silvia Grazietta Foddai Elena Rubini Dario Roccatello Savino Sciascia |
| author_facet | Alice Barinotti Massimo Radin Irene Cecchi Silvia Grazietta Foddai Elena Rubini Dario Roccatello Savino Sciascia |
| author_sort | Alice Barinotti |
| collection | DOAJ |
| description | Chronic kidney disease (CKD) is a widely diffuse pathological condition which deeply impacts upon an affected patient’s quality of life and its worldwide rate is predicted to further rise. The main biological mechanism underlying CKD is renal fibrosis, a non-reversible process representing, for the affected system, a point of no return of tissue damage and dysfunction, deeply reducing the possible therapeutic strategies at the disposal of physicians. The best tool clinicians can use to address the extent of renal fibrosis at any level (glomeruli, tubule-interstitium, vasculature) is kidney biopsy that, despite its overall safety, remains an invasive procedure showing some shortcomings. Thus, the identification of novel non-invasive renal fibrosis biomarkers would be of fundamental importance. Here, when systematically reviewing the available evidence on serological biomarkers associated with renal fibrosis evaluated in patients suffering from CKD in the last five years, we found that despite the presence of several promising biomarkers, the level of observed evidence is still very scattered. Probably, the use of multiple measures capable of addressing different aspects involved in this condition would be the most suitable way to capture the high complexity characterizing the renal fibrotic process, having consequently a great impact on clinical practice by maximizing prevention, diagnosis, and management. |
| first_indexed | 2024-03-09T18:17:09Z |
| format | Article |
| id | doaj.art-e43cdcbeaf514ee4a17d62f4c5e25045 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T18:17:09Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-e43cdcbeaf514ee4a17d62f4c5e250452023-11-24T08:39:22ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-11-0123221413910.3390/ijms232214139Serum Biomarkers of Renal Fibrosis: A Systematic ReviewAlice Barinotti0Massimo Radin1Irene Cecchi2Silvia Grazietta Foddai3Elena Rubini4Dario Roccatello5Savino Sciascia6University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, 10154 Turin, ItalyUniversity Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, 10154 Turin, ItalyUniversity Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, 10154 Turin, ItalyUniversity Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, 10154 Turin, ItalyUniversity Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, 10154 Turin, ItalyUniversity Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, 10154 Turin, ItalyUniversity Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, 10154 Turin, ItalyChronic kidney disease (CKD) is a widely diffuse pathological condition which deeply impacts upon an affected patient’s quality of life and its worldwide rate is predicted to further rise. The main biological mechanism underlying CKD is renal fibrosis, a non-reversible process representing, for the affected system, a point of no return of tissue damage and dysfunction, deeply reducing the possible therapeutic strategies at the disposal of physicians. The best tool clinicians can use to address the extent of renal fibrosis at any level (glomeruli, tubule-interstitium, vasculature) is kidney biopsy that, despite its overall safety, remains an invasive procedure showing some shortcomings. Thus, the identification of novel non-invasive renal fibrosis biomarkers would be of fundamental importance. Here, when systematically reviewing the available evidence on serological biomarkers associated with renal fibrosis evaluated in patients suffering from CKD in the last five years, we found that despite the presence of several promising biomarkers, the level of observed evidence is still very scattered. Probably, the use of multiple measures capable of addressing different aspects involved in this condition would be the most suitable way to capture the high complexity characterizing the renal fibrotic process, having consequently a great impact on clinical practice by maximizing prevention, diagnosis, and management.https://www.mdpi.com/1422-0067/23/22/14139chronic kidney diseaserenal fibrosisbiomarkers |
| spellingShingle | Alice Barinotti Massimo Radin Irene Cecchi Silvia Grazietta Foddai Elena Rubini Dario Roccatello Savino Sciascia Serum Biomarkers of Renal Fibrosis: A Systematic Review International Journal of Molecular Sciences chronic kidney disease renal fibrosis biomarkers |
| title | Serum Biomarkers of Renal Fibrosis: A Systematic Review |
| title_full | Serum Biomarkers of Renal Fibrosis: A Systematic Review |
| title_fullStr | Serum Biomarkers of Renal Fibrosis: A Systematic Review |
| title_full_unstemmed | Serum Biomarkers of Renal Fibrosis: A Systematic Review |
| title_short | Serum Biomarkers of Renal Fibrosis: A Systematic Review |
| title_sort | serum biomarkers of renal fibrosis a systematic review |
| topic | chronic kidney disease renal fibrosis biomarkers |
| url | https://www.mdpi.com/1422-0067/23/22/14139 |
| work_keys_str_mv | AT alicebarinotti serumbiomarkersofrenalfibrosisasystematicreview AT massimoradin serumbiomarkersofrenalfibrosisasystematicreview AT irenececchi serumbiomarkersofrenalfibrosisasystematicreview AT silviagraziettafoddai serumbiomarkersofrenalfibrosisasystematicreview AT elenarubini serumbiomarkersofrenalfibrosisasystematicreview AT darioroccatello serumbiomarkersofrenalfibrosisasystematicreview AT savinosciascia serumbiomarkersofrenalfibrosisasystematicreview |